Office-Based Y-90

Integrating Y-90 Into Your Office-Based Suite

Office-Based Y-90 Solutions from Sirtex

Product Support – SIR-Spheres^® Y-90 resin microspheres offer the flexibility to order, map then treat your patients with 3 delivery options, 5 days a week so that you can focus on expedited patient treatment, not the schedule.
Clinical Support – The Medical Science Liaison team is readily available to engage in scientific discussions and provide best practices that may guide you in making clinical decisions.
Licensing Support – Our seasoned Radiation Safety team can help your office navigate complex local and national regulations.
Reimbursement Support – Sirtex’s dedicated Healthcare Economics team will help inform your decision-making process prior to launching a Y-90 program in your office.
Launch Support – Dedicated office-based team members can guide you in your discovery process to decide if a Y-90 program is right for your office, and prior to launch determine the best workflow for patients.

OBIS Product Sheet: Patient-Focused Care

OBIS Case Study: Increasing Access for mCRC Patients who are Candidates for SIRT

Improved Y-90 Patient Experience in a Multispecialty Oncology Practice

To learn more, please complete the form below.

* We are collecting this personal information in order to respond to the inquiry you are sending via this form. SIRTEX understands the importance of protecting your information and will use your information for the sole purpose of responding to your inquiry.

Indications for Use: SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intrahepatic artery chemotherapy (IHAC) . of FUDR (Floxuridine). Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.